322 related articles for article (PubMed ID: 34927450)
21. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach.
Drożdż K; Nabrdalik K; Kwiendacz H; Hendel M; Olejarz A; Tomasik A; Bartman W; Nalepa J; Gumprecht J; Lip GYH
Cardiovasc Diabetol; 2022 Nov; 21(1):240. PubMed ID: 36371249
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
[TBL] [Abstract][Full Text] [Related]
23. Associations of Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease With Cardiovascular Healthy Outcomes.
Wu W; Ma W; Yuan S; Feng A; Li L; Zheng H; Li S; He N; Huang Y; Lyu J
J Am Heart Assoc; 2023 Dec; 12(23):e031440. PubMed ID: 38014686
[TBL] [Abstract][Full Text] [Related]
24. Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods.
Lee SM; Hwangbo S; Norwitz ER; Koo JN; Oh IH; Choi ES; Jung YM; Kim SM; Kim BJ; Kim SY; Kim GM; Kim W; Joo SK; Shin S; Park CW; Park T; Park JS
Clin Mol Hepatol; 2022 Jan; 28(1):105-116. PubMed ID: 34649307
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound-Based Machine Learning Approach for Detection of Nonalcoholic Fatty Liver Disease.
Tahmasebi A; Wang S; Wessner CE; Vu T; Liu JB; Forsberg F; Civan J; Guglielmo FF; Eisenbrey JR
J Ultrasound Med; 2023 Aug; 42(8):1747-1756. PubMed ID: 36807314
[TBL] [Abstract][Full Text] [Related]
26. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.
Chahal D; Sharma D; Keshavarzi S; Arisar FAQ; Patel K; Xu W; Bhat M
Hepatol Int; 2022 Apr; 16(2):325-336. PubMed ID: 35178663
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
[TBL] [Abstract][Full Text] [Related]
28. Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.
McHenry S; Park Y; Davidson NO
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2638-2640. PubMed ID: 34044131
[TBL] [Abstract][Full Text] [Related]
29. Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study.
Roca-Fernandez A; Banerjee R; Thomaides-Brears H; Telford A; Sanyal A; Neubauer S; Nichols TE; Raman B; McCracken C; Petersen SE; Ntusi NA; Cuthbertson DJ; Lai M; Dennis A; Banerjee A
J Hepatol; 2023 Nov; 79(5):1085-1095. PubMed ID: 37348789
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification.
Baratta F; D'Erasmo L; Bini S; Pastori D; Angelico F; Del Ben M; Arca M; Di Costanzo A
Atherosclerosis; 2022 Sep; 357():51-59. PubMed ID: 36058083
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
33. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease.
Corey KE; Chalasani N
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1077-84; quiz e59-60. PubMed ID: 23962548
[TBL] [Abstract][Full Text] [Related]
34. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
[TBL] [Abstract][Full Text] [Related]
35. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
36. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
37. Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
Kaplan A; Simon TG; Henson JB; Wang T; Zheng H; Osganian SA; Rosenblatt R; Lake J; Corey KE
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):400-404. PubMed ID: 32235172
[TBL] [Abstract][Full Text] [Related]
38. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
Ishido S; Tamaki N; Takahashi Y; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Kurosaki M; Izumi N
BMC Gastroenterol; 2023 Jun; 23(1):211. PubMed ID: 37330485
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular risk factors in non-alcoholic fatty liver disease.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
[TBL] [Abstract][Full Text] [Related]
40. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
Morrison AE; Zaccardi F; Khunti K; Davies MJ
Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
